Trialssemaglutidesitagliptinliver transplantuniversity health network

Toronto trial tests oral semaglutide against sitagliptin in liver transplant patients

The Phase 4 randomized study, active but not recruiting, compares glycemic control, body weight and tolerability in recipients with poorly controlled diabetes.

By Priya Raman · Science Reporter

Oct 14 08:00 ETSource: ClinicalTrials.gov

The wire

01University Health Network's NCT05195944 began October 2022 and randomizes liver transplant recipients with poorly controlled diabetes to once-daily oral semaglutide or once-daily sitagliptin.
02Transplant recipients are routinely excluded from incretin trials, so clinicians managing post-transplant metabolic disease have little controlled data to work from.
03Listed conditions also include NASH and diabetes complications; the trial is active not recruiting and no results have been posted.

From the source

Semaglutide vs Sitagliptin
NCT05195944 · PHASE4 · ACTIVE NOT RECRUITING · Sponsor: University Health Network, Toronto · Conditions: Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT05195944